文献速递消化道肿瘤放疗放疗物理与技术

评估六种扩散加权MRI模型在胰腺癌患者新辅助放化疗疗效评价中的作用

Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-05-04

本研究在3T下对晚期胰腺导管腺癌患者进行重复基线DWI采集,并对(交界)可切除患者在新辅助放化疗前后采集,比较6种DWI模型。单指数模型拟合优度最低,扩散参数在各模型间强相关且呈治疗相关升高;双单指数模型(ADCfast与ADCslow)能区分非扩散与扩散相关效应,且可在多数商用扫描仪上快速完成。

要点

  • 单指数模型在肿瘤和正常胰腺的拟合优度均最低。
  • 非扩散参数的组织对比度更高,扩散参数的重复性更好。
  • 所有模型均能在9例中5例的至少一个参数上识别出超过重复性的个体治疗效应。

核心结论

  • 所有研究的DWI模型均可用于个体治疗评价,治疗相关变化超过重复性。
  • 双单指数拟合(ADCfast与ADCslow)能区分非扩散与扩散相关效应,测量快速且可在多数商用扫描仪上完成,是放疗疗效评价中较先进多参数模型的有吸引力的替代方案。

研究设计与样本

  • 在3T下以b=0-600 s/mm²采集DWI图像。
  • 14例晚期胰腺导管腺癌患者接受2次独立治疗前采集,9例(交界)可切除胰腺导管腺癌患者在新辅助放化疗前后采集。
  • 数据以单指数(ADC)、双单指数至b=0和100 s/mm²(ADCfast)及b=100和600 s/mm²(ADCslow)、IVIM模型(D*自由与固定)、三指数模型(D、f1、f2)和拉伸指数模型(DDC、α)拟合。

主要发现

  • 单指数模型在肿瘤(R²=0.94)和表现正常胰腺(R²=0.88)中拟合优度最低。
  • 非扩散参数(ADCfast、f、D*、f1、f2、α)的肿瘤与正常组织对比度更高,扩散参数(ADC、ADCslow、D、DDC)重复性更好。
  • 扩散参数在各模型间强相关(rho≥0.81),并显示总体治疗相关升高。
  • 所有模型均能识别个体治疗效应,在9例中5例的至少一个参数上变化超过重复性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare 6 diffusion-weighted imaging (DWI) MRI models for response evaluation in patients with pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS: DWI images were acquired at 3T for b = 0-600 s/mm2 in fourteen patients with advanced PDAC during 2 separate pretreatment sessions and 9 patients with (borderline) resectable PDAC pre and post neoadjuvant chemoradiation. Data was fitted with a mono-exponential (ADC), double mono-exponential to b = 0 and 100 s/mm2 (ADCfast), and b = 100 and 600 s/mm2 (ADCslow), IVIM model with D* free (D, f, D*) and fixed (D, f), tri-exponent (D, f1, f2), and stretched exponent model (DDC, α). Goodness of fit (adjusted R2), tumor to normal tissue contrast, repeatability (coefficient of variation), and parameter correlations (Spearman's rho) were assessed for the repeated measures. Treatment induced changes were assessed and compared to the repeatability. RESULTS: The mono-exponential model had the lowest goodness of fit in both tumor (R2 = 0.94) and normal-appearing pancreas (R2 = 0.88). Tumour to normal tissue contrast was higher for the 'non-diffusion' parameters (ADCfast, f, D*, f1, f2, α), with better repeatability for the diffusion parameters (ADC, ADCslow, D, DDC). Diffusion parameters were strongly correlated between the models (rho ≥0.81) and showed a general treatment associated increase. All models were able to identify individual treatment effects, showing a change greater than the repeatability in 5 out of 9 patients for at least one of the parameters. CONCLUSIONS: Individual treatment evaluation is possible with all investigated DWI models, with treatment associated changes exceeding the repeatability. The double monoexponential fit with ADCfast and ADCslow is able to discriminate between non-diffusion and diffusion related effects, is measured fast and can be performed on most commercial scanners, making it an attractive alternative for the more advanced multiparametric models in radiotherapy treatment evaluation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Klaassen R, Gurney-Champion OJ, Engelbrecht MRW, et al. Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. Int J Radiat Oncol Biol Phys. 2018. PMID: 29891208. doi:10.1016/j.ijrobp.2018.04.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。